Finoriq research workspace
aTYR PHARMA INC (ATYR) SEC Filings & Filing Highlights
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery. Review ATYR SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
- Company
- aTYR PHARMA INC (ATYR)
- Ticker
- ATYR
- Market Cap
- $47.8M
- Latest Price
- $0.488
- Industry
- Biotech & Pharma
aTYR PHARMA INC (ATYR) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for aTYR PHARMA INC (ATYR).
| Event | Form | Date |
|---|---|---|
| aTYR PHARMA INC: Exchange listing issueAs previously disclosed, on December 4, 2025, aTyr Pharma, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the listin... | 8-K3.01 | 2026-06-08 |
| aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond J...aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond June 2026 © 2026 aTyr Pharma Exhibit 99.1 | 8-K7.01 | 2026-06-01 |
| aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate UpdateaTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update | 8-K2.02 | 2026-05-15 |
| aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond M...aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond May 11, 2026 © 2026 aTyr Pharma Exhibit 99.1 | 8-K8.01 | 2026-05-11 |
| aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond M...aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond May 11, 2026 © 2026 aTyr Pharma Exhibit 99.1 | 8-K7.01 | 2026-05-11 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.